Heptares And Complix Raise Series B Funds To Advance Preclinical Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
GPCR-focused Heptares and the protein scaffold company Complix complete a seemingly rare event for European biotechs, a second round of VC funding.
You may also be interested in...
Aileron Overcoming Spirited Debate About Stapled Peptides
The new, promising class of drugs is rolling toward the clinic, but a respected research group recently thrust a stick in the spokes and prompted a call for wider access to the technology.
Shire Exercises Option On Heptares' Preclinical Candidate In $190 Million Deal
The U.K.'s G-protein coupled receptor specialist, Heptares, could receive up to $190 million plus royalties from Shire as it concludes its first product out-licensing agreement.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.